Zomedica

Zomedica Corp. engages in the discovery, development, and commercialization of pharmaceuticals for companion animals, including dogs, cats, and horses. The company is headquartered in Ann Arbor, Michigan and currently employs 141 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice economics. Its Diagnostics segment consists of TRUFORMA, VETGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi Loop and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field therapy.